The Epidemiology of Hospital-Treated Alopecia Areata in Denmark, 1995 –2016
ConclusionThis cohort study reported incidence rates and prevalence over time and characteristics of individuals with hospital-treated AA in Denmark, which are in agreement with those previously reported in this population. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - April 16, 2024 Category: Dermatology Source Type: research
Treatment Options for Alopecia Areata in Children and Adolescents
Paediatr Drugs. 2024 Mar 11. doi: 10.1007/s40272-024-00620-2. Online ahead of print.ABSTRACTAlopecia areata (AA) lifetime incidence is around 2%, with many patients first experiencing symptoms during childhood. However, ritlecitinib is the only FDA-approved treatment for pediatric patients 12 years and older. This review outlines reported topical, injectable, and oral treatment options for pediatric patients with AA. Clinical studies were obtained via a PubMed search using the following search terms: alopecia areata, areata, universalis, or totalis and medication, therapy, treatment, drug, or management. Only studies with ...
Source: Paediatric Drugs - March 11, 2024 Category: Pediatrics Authors: Linnea L Westerkam Diana B McShane Elizabeth L Nieman Dean S Morrell Source Type: research
Treatment Options for Alopecia Areata in Children and Adolescents
Paediatr Drugs. 2024 Mar 11. doi: 10.1007/s40272-024-00620-2. Online ahead of print.ABSTRACTAlopecia areata (AA) lifetime incidence is around 2%, with many patients first experiencing symptoms during childhood. However, ritlecitinib is the only FDA-approved treatment for pediatric patients 12 years and older. This review outlines reported topical, injectable, and oral treatment options for pediatric patients with AA. Clinical studies were obtained via a PubMed search using the following search terms: alopecia areata, areata, universalis, or totalis and medication, therapy, treatment, drug, or management. Only studies with ...
Source: Paediatric Drugs - March 11, 2024 Category: Pediatrics Authors: Linnea L Westerkam Diana B McShane Elizabeth L Nieman Dean S Morrell Source Type: research
Treatment Options for Alopecia Areata in Children and Adolescents
Paediatr Drugs. 2024 Mar 11. doi: 10.1007/s40272-024-00620-2. Online ahead of print.ABSTRACTAlopecia areata (AA) lifetime incidence is around 2%, with many patients first experiencing symptoms during childhood. However, ritlecitinib is the only FDA-approved treatment for pediatric patients 12 years and older. This review outlines reported topical, injectable, and oral treatment options for pediatric patients with AA. Clinical studies were obtained via a PubMed search using the following search terms: alopecia areata, areata, universalis, or totalis and medication, therapy, treatment, drug, or management. Only studies with ...
Source: Paediatric Drugs - March 11, 2024 Category: Pediatrics Authors: Linnea L Westerkam Diana B McShane Elizabeth L Nieman Dean S Morrell Source Type: research
Treatment Options for Alopecia Areata in Children and Adolescents
Paediatr Drugs. 2024 Mar 11. doi: 10.1007/s40272-024-00620-2. Online ahead of print.ABSTRACTAlopecia areata (AA) lifetime incidence is around 2%, with many patients first experiencing symptoms during childhood. However, ritlecitinib is the only FDA-approved treatment for pediatric patients 12 years and older. This review outlines reported topical, injectable, and oral treatment options for pediatric patients with AA. Clinical studies were obtained via a PubMed search using the following search terms: alopecia areata, areata, universalis, or totalis and medication, therapy, treatment, drug, or management. Only studies with ...
Source: Paediatric Drugs - March 11, 2024 Category: Pediatrics Authors: Linnea L Westerkam Diana B McShane Elizabeth L Nieman Dean S Morrell Source Type: research
Treatment Options for Alopecia Areata in Children and Adolescents
Paediatr Drugs. 2024 Mar 11. doi: 10.1007/s40272-024-00620-2. Online ahead of print.ABSTRACTAlopecia areata (AA) lifetime incidence is around 2%, with many patients first experiencing symptoms during childhood. However, ritlecitinib is the only FDA-approved treatment for pediatric patients 12 years and older. This review outlines reported topical, injectable, and oral treatment options for pediatric patients with AA. Clinical studies were obtained via a PubMed search using the following search terms: alopecia areata, areata, universalis, or totalis and medication, therapy, treatment, drug, or management. Only studies with ...
Source: Paediatric Drugs - March 11, 2024 Category: Pediatrics Authors: Linnea L Westerkam Diana B McShane Elizabeth L Nieman Dean S Morrell Source Type: research
Treatment Options for Alopecia Areata in Children and Adolescents
Paediatr Drugs. 2024 Mar 11. doi: 10.1007/s40272-024-00620-2. Online ahead of print.ABSTRACTAlopecia areata (AA) lifetime incidence is around 2%, with many patients first experiencing symptoms during childhood. However, ritlecitinib is the only FDA-approved treatment for pediatric patients 12 years and older. This review outlines reported topical, injectable, and oral treatment options for pediatric patients with AA. Clinical studies were obtained via a PubMed search using the following search terms: alopecia areata, areata, universalis, or totalis and medication, therapy, treatment, drug, or management. Only studies with ...
Source: Paediatric Drugs - March 11, 2024 Category: Pediatrics Authors: Linnea L Westerkam Diana B McShane Elizabeth L Nieman Dean S Morrell Source Type: research
Treatment Options for Alopecia Areata in Children and Adolescents
AbstractAlopecia areata (AA) lifetime incidence is around 2%, with many patients first experiencing symptoms during childhood. However, ritlecitinib is the only FDA-approved treatment for pediatric patients 12 years and older. This review outlines reported topical, injectable, and oral treatment options for pediatric patients with AA. Clinical studies were obtained via a PubMed search using the following search terms: alopecia areata, areata, universalis, or totalis and medication, therapy, treatment, drug, or management. Only studies with pediatric patients were included in this review. Commonly used therapies, including ...
Source: Pediatric Drugs - March 11, 2024 Category: Pediatrics Source Type: research
Modified Mediterranean Diet With Anti-Inflammatory Features and Oral Butyrate Supplementation Appears to Have No Effect in Cases of Alopecia Areata Universalis and Totalis: Experience With 20 Patients
Actas Dermosifiliogr. 2023 Nov 10:S0001-7310(23)00923-7. doi: 10.1016/j.ad.2023.01.028. Online ahead of print.NO ABSTRACTPMID:37952836 | DOI:10.1016/j.ad.2023.01.028 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - November 12, 2023 Category: Dermatology Authors: O M Moreno-Arrones J I Botella-Carretero M Garriga S Va ñó-Galván Source Type: research
Modified Mediterranean Diet With Anti-Inflammatory Features and Oral Butyrate Supplementation Appears to Have No Effect in Cases of Alopecia Areata Universalis and Totalis: Experience With 20 Patients
Actas Dermosifiliogr. 2023 Nov 10:S0001-7310(23)00923-7. doi: 10.1016/j.ad.2023.01.028. Online ahead of print.NO ABSTRACTPMID:37952836 | DOI:10.1016/j.ad.2023.01.028 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - November 12, 2023 Category: Dermatology Authors: O M Moreno-Arrones J I Botella-Carretero M Garriga S Va ñó-Galván Source Type: research
Modified Mediterranean Diet With Anti-Inflammatory Features and Oral Butyrate Supplementation Appears to Have No Effect in Cases of Alopecia Areata Universalis and Totalis: Experience With 20 Patients
Actas Dermosifiliogr. 2023 Nov 10:S0001-7310(23)00923-7. doi: 10.1016/j.ad.2023.01.028. Online ahead of print.NO ABSTRACTPMID:37952836 | DOI:10.1016/j.ad.2023.01.028 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - November 12, 2023 Category: Dermatology Authors: O M Moreno-Arrones J I Botella-Carretero M Garriga S Va ñó-Galván Source Type: research
Modified Mediterranean Diet With Anti-Inflammatory Features and Oral Butyrate Supplementation Appears to Have No Effect in Cases of Alopecia Areata Universalis and Totalis: Experience With 20 Patients
Actas Dermosifiliogr. 2023 Nov 10:S0001-7310(23)00923-7. doi: 10.1016/j.ad.2023.01.028. Online ahead of print.NO ABSTRACTPMID:37952836 | DOI:10.1016/j.ad.2023.01.028 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - November 12, 2023 Category: Dermatology Authors: O M Moreno-Arrones J I Botella-Carretero M Garriga S Va ñó-Galván Source Type: research
Modified Mediterranean Diet With Anti-Inflammatory Features and Oral Butyrate Supplementation Appears to Have No Effect in Cases of Alopecia Areata Universalis and Totalis: Experience With 20 Patients
Actas Dermosifiliogr. 2023 Nov 10:S0001-7310(23)00923-7. doi: 10.1016/j.ad.2023.01.028. Online ahead of print.NO ABSTRACTPMID:37952836 | DOI:10.1016/j.ad.2023.01.028 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - November 12, 2023 Category: Dermatology Authors: O M Moreno-Arrones J I Botella-Carretero M Garriga S Va ñó-Galván Source Type: research
Modified Mediterranean Diet With Anti-Inflammatory Features and Oral Butyrate Supplementation Appears to Have No Effect in Cases of Alopecia Areata Universalis and Totalis: Experience With 20 Patients
Actas Dermosifiliogr. 2023 Nov 10:S0001-7310(23)00923-7. doi: 10.1016/j.ad.2023.01.028. Online ahead of print.NO ABSTRACTPMID:37952836 | DOI:10.1016/j.ad.2023.01.028 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - November 12, 2023 Category: Dermatology Authors: O M Moreno-Arrones J I Botella-Carretero M Garriga S Va ñó-Galván Source Type: research
